Alleviates Sarcopenia in Senescence-Accelerated Mouse-Prone 8 Mice.

Abstract

, an intestinal bacterium, has garnered attention for its association with metabolic health and anti-inflammatory properties. However, its potential role in mitigating sarcopenia, particularly in the senescence-accelerated mouse-prone 8 (SAMP8) model, remains unexplored. In this study, we aimed to evaluate the potential effects ofsupplementation on sarcopenia and its underlying mechanisms. Seven-month-old SAMP8 mice were administeredfor 3 months.supplementation enhanced grip strength and skeletal muscle mass, suppressed cellular senescence, improved the balance between protein degradation and synthesis, increased total ATP, and improved mitochondrial biogenesis. Analysis of the effects ofon gut microbiome using 16S rRNA sequencing showed that supplementation withshifted the gut microbiota composition, alleviated gut dysbiosis, preserved gut barrier integrity, and reduced the protein expression of inflammatory cytokines in the intestine. Additionally, extracellular vesicles derived frompromoted myogenesis and suppressed dexamethasone-induced atrophy in C2C12 myoblasts. These findings suggest that supplementation withmitigates sarcopenia by suppressing inflammation and improving the gut microenvironment, highlighting the potential ofas a new therapeutic candidate to treat sarcopenia.